Aytu BioPharma Inc
Company Profile
Business description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Contact
7900 East Union Avenue
Suite 920
DenverCO80237
USAT: +1 720 437-6580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
83
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,215.59 | 10.04 | -0.12% |
| DAX 40 | 24,228.14 | 11.75 | -0.05% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,656.55 | 10.93 | 0.11% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |